Medical Developments International (MVP) H1 2026 earnings summary

Executive summary

• Group revenue increased 8% year-over-year to $21.6 million, driven by 18% growth in Pain Management and a 10% decline in Respiratory, mainly due to softer US demand.

• Net loss after tax was $0.2 million, compared to a $0.3 million profit in the prior period, reflecting lower margins in Europe and reduced earnings in Respiratory.

• Positive operating cashflow of $0.3 million, an improvement of $1.0 million from the prior period; closing cash balance at $16.9 million.

• Strategic focus on accelerating Penthrox volume growth, margin improvement, and expanding pediatric label in Europe, with most country-level approvals expected by August.

• Strengthened commercial and medical initiatives to drive adoption and expand market access.

Financial highlights

• Group revenue up 8% year-over-year to $21.6 million; Pain Management segment up 18% to $15.4 million, Respiratory segment down 10% to $6.2 million.

• EBIT was a $0.3 million loss, compared to a $0.2 million profit in the prior year; excluding FX impacts, EBIT improved by $0.6 million.

• Net loss after tax was $0.2 million, versus a $0.3 million profit year-over-year.

• Operating cash flow improved by $1.0 million, reaching positive territory at $0.3 million; free cashflow also improved.

• Cash at period end was $16.9 million, supporting future growth initiatives.

Outlook and guidance

• Expectation of seasonally softer demand and lower earnings in the Respiratory segment for the second half of FY26.

• Anticipate finalizing pediatric indication approvals in Europe and supporting new label launches in FY26.

• Continued execution of targeted commercial and medical initiatives to expand access and clinical engagement, especially in hospitals and pediatric markets.